# Ceftriaxone as Home IV for Staph Infections

> **NCT04141787** · PHASE4 · UNKNOWN · sponsor: **Vancouver Island Health Authority** · enrollment: 310 (estimated)

## Conditions studied

- Staphylococcal Infections
- Osteomyelitis
- CNS Infection
- Septic Arthritis
- Diabetic Foot Infection
- Vertebral Osteomyelitis
- Abscess
- Coagulase Negative Staphylococcal Infection

## Interventions

- **DRUG:** Ceftriaxone
- **DRUG:** Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)

## Key facts

- **NCT ID:** NCT04141787
- **Lead sponsor:** Vancouver Island Health Authority
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-11
- **Primary completion:** 2023-07
- **Final completion:** 2024-03-30
- **Target enrollment:** 310 (ESTIMATED)
- **Last updated:** 2019-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04141787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04141787, "Ceftriaxone as Home IV for Staph Infections". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04141787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*